Pulse Biosciences Inc. has recruited Maria Sainz to its Board of Directors.

“We are delighted to welcome Maria to our Board of Directors,” Pulse Biosciences’ Board Co-Chairman Robert W. Duggan. “She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional markets with our patient-first mission.”

Sainz has more than three decades of experience in healthcare technology, including 18 years in CEO roles leading publicly traded companies and venture-backed startups. Currently, she is president and CEO of Hyperfine Inc., a medical technology company with a commercial stage portable brain MRI system. Previously, she was president and CEO of Aegea Medical, a venture capital-backed women’s health company; president and CEO of CardioKinetix Inc., a venture capital-backed company in interventional heart failure therapy; and president and CEO of Concentric Medical, a venture capital-backed stroke thrombectomy company.

Prior to her CEO roles, Sainz served in various leadership capacities at Guidant Corporation and Boston Scientific Corporation, including as strategic advisor to the chief operating officer, president of the Cardiac Surgery Division, vice president of Global Marketing for Vascular Intervention, and vice president for CRM and Cardiac Surgery in EMEA.

In addition, Sainz has served on the board of numerous companies including Shockwave Medical, Spectranetics Corp., Avanos Medical, Orthofix Medical Inc., Hyperfine, and several private medical device companies. Sainz earned a master’s degree in English from the Complutense University of Madrid and a master’s degree in international management from Thunderbird School of Global Management.

“I am honored to join Pulse’s Board of Directors at this pivotal stage, as its first three programs advance through key clinical, regulatory, and commercial milestones,” Sainz stated. “Pulse is very well positioned and Nanosecond PFA technology is exceptionally differentiated and has critical applications in large clinical markets. I look forward to working with the leadership team and contributing strategic guidance as the company expands its clinical evidence, accelerates commercialization, and drives short, intermediate, and long-term value creation.”

Pulse Biosciences is a bioelectric medicine company committed to health innovation that can potentially improve patients’ quality of life. The company’s proprietary nPulse technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is actively pursuing the development of its nPulse technology for use in treating atrial fibrillation and in a select few other markets where it could positively impact healthcare for both patients and providers, such as surgical soft tissue ablation.